1Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology [J]. J Clin Oncol,2001,19(6):1865～1878.
2Shih C,Padhy LC, Murray M. Transforming genes of carainomas and neuroblastomas introduced into mouse fibrolasts[J]. Nature, 1981,290:261～264.
3Coussens L. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene[J]. Science,1985,230:1132～1139.
4Allred DC, Clark GM, Molina R, et al. Overexpression of HEr-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer[J]. Hum Pathol, 1992,23(9):974～979.
5Gilboa L, Ben Levy R, Yarden Y, et al. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits[J].J Biol Chem, 1995,270(13): 7061～7067.
6Graus Porta D, Beerli RR, Daly JM, et al. ErbB -2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling[J]. EMBO J, 1997,16(7): 1647～1655.
7Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors[J]. FEBS Lett, 1999,447(2～3):227～231.
8Pinkas- Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGFlike ligands: cell lineage determination and oncogenesis through combinatorial signaling[J]. J Mammary Gland Biol Neoplasia, 1997,2(2):97～107.
9Tzahar E, Levkowitz G, Karunagaran D, et al. ErbB -3 and ErbB -4function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isofoms[J].J Biol Chem, 1994,269(40):25226 ～ 25233.
10Huang CS, Chen YC, WANG M, et al. HER- 2/neu overexpression in Chinese breast cancers: correlation with other prognostic factors [J].JFormos Med Assoc, 1995,94:660～665.
同被引文献41
1Delaloye AB.The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).Leuk Lymphoma,2003,44 (Suppl4):s29-s36.
2Hagenbeek A.Radioimmunotherapy for NHL:experience of 90 Y-ibritumomab tiuxetan in clinical practice.Leuk Lymphoma,2003,44 (Suppl4):s37-s47.
3Fl'avia OP,Hans G,Luiz MN,et al.Concomitant presentation of Hashimoto's thyroiditis and Maltoma of the thyroid in a twenty-year-old man with a rapidly growing mass in the neck.Thyroid,2000,10(9):833-835.
4Pasieka JL.Hashimoto's disease and thyroid lymphoma:role of the surgeon.World J Surg,2000,24(8):966-970.
5Gregory AD,Lester DR,Thompson,et al.Malignant lymphoma of the thyroid gland.Am J Surg Pathol,2000,24 (5):623-639.
6Mi SK,Jai HG.Critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the Stomach and Small Intestine.Am J Surg Pathol,2003,27(6):790-798.
7Chetty R,O'Leary JJ,Biddolph SC,et al.Immunohistochemical detection of p53 and Bcl-2 proteins in Hashimoto's thyroiditis and primary thyroid lymphomas.J Clin Pathol,1995,48(3):239-241.
8Alfred CF,Jacques D.Histopathology of nodal and extranodal non-Hodgking's lymphomas.Berlin:Springer-Verlag Berlin Heidelberg,2004.289-292.
9Tetsuya T,Dong Z,Takayama H,et al.Frequent mutations of Fas gene in thyroid lymphoma.Cancer Res,2001,61 (4):1382-1385.
10Plumas J,Jacob MC,Chaperot L,et al.Tumor B Cell from Non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1) -mediated apoptosis.Blood,1998,91(8):2875-2885.
